Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

Molecular Cancer Therapeutics
Bernard M TijinkGuus A M S van Dongen

Abstract

The approximately 15-kDa variable domains of camelid heavy-chain-only antibodies (called Nanobodies) can easily be formatted as multivalent or multispecific single-chain proteins. Because of fast excretion, however, they are less suitable for therapy of cancer. In this study, we aimed for improved tumor targeting of a bivalent anti-epidermal growth factor receptor (EGFR) Nanobody (alphaEGFR-alphaEGFR) by fusion to a Nanobody unit binding to albumin (alphaAlb). Biodistributions of alphaEGFR-alphaEGFR, alphaEGFR-alphaEGFR-alphaAlb ( approximately 50 kDa), alphaTNF-alphaTNF-alphaAlb (control, binding tumor necrosis factor-alpha), and the approximately 150-kDa anti-EGFR antibody cetuximab were compared in A431 xenograft-bearing mice. The proteins were radiolabeled with (177)Lu to facilitate quantification. Tumor uptake of (177)Lu-alphaEGFR-alphaEGFR decreased from 5.0 +/- 1.4 to 1.1 +/- 0.1 %ID/g between 6 and 72 h after injection. Due to its rapid blood clearance, tumor-to-blood ratios >80 were obtained within 6 h after injection. Blood clearance became dramatically slower and tumor uptake became significantly higher by introduction of alphaAlb. Blood levels of alphaEGFR-alphaEGFR-alphaAlb were 21.2 +/- 2.5, 11.9 +/- 0.6, and 4.0 ...Continue Reading

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·P YehR Fleer
Jan 1, 1993·The Journal of Cell Biology·H MasuiJ Mendelsohn
Jun 3, 1993·Nature·C Hamers-CastermanR Hamers
Feb 1, 1996·Trends in Biotechnology·S M Chamow, A Ashkenazi
May 1, 1996·Nuclear Medicine and Biology·W E MeijsJ D Herscheid
Nov 1, 1996·Clinical and Experimental Immunology·M M NewkirkP Apostolakos
Jun 25, 1998·International Journal of Cancer. Journal International Du Cancer·F B van GogG A van Dongen
Aug 3, 1999·Nature Biotechnology·A P ChapmanD J King
Oct 29, 2000·The Journal of Biological Chemistry·K Els ConrathS Muyldermans
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Virna Cortez-RetamozoHilde Revets
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Iris VerelGuus A M S van Dongen
Jul 18, 2002·The Journal of Biological Chemistry·Mark S DennisLisa A Damico
Jan 7, 2003·Nature Medicine·Peter J Hudson, Christelle Souriau
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Dec 13, 2005·Analytical Biochemistry·Robert KarlssonDavid G Myszka
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Jun 2, 2006·Cancer Immunology, Immunotherapy : CII·Rob C RooversPaul M P van Bergen en Henegouwen
Jan 11, 2007·Cancer Research·Mark S DennisRalph Schwall

❮ Previous
Next ❯

Citations

Jun 17, 2009·Medical Microbiology and Immunology·Janusz WesolowskiFriedrich Koch-Nolte
Feb 5, 2010·Biotechnology Letters·A ConstantinouM P Deonarain
Dec 13, 2012·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Daniel L SmithJennifer Sims-Mourtada
Apr 13, 2010·Parasitology·Magdalena Radwanska
Dec 29, 2009·Médecine sciences : M/S·Patrick Chames, Daniel Baty
Jul 25, 2009·The Journal of Biological Chemistry·Roland StorkRoland E Kontermann
Mar 2, 2010·Cancer Biotherapy & Radiopharmaceuticals·Robert M SharkeyDavid M Goldenberg
Aug 5, 2011·Diabetes, Obesity & Metabolism·B Ahrén, B Burke
Mar 31, 2012·Circulation Research·Alexis BroisatNick Devoogdt
Jun 11, 2011·Microbial Cell Factories·Ario de Marco
Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Roland E Kontermann
Mar 5, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dafne Müller, Roland E Kontermann
Oct 15, 2009·Future Microbiology·Stefan Magez, Magdalena Radwanska
Mar 15, 2011·Immunotherapy·Robert M Sharkey, David M Goldenberg
Jun 5, 2013·Nanomedicine·Gholamreza Hassanzadeh-GhassabehSerge Muyldermans
Oct 15, 2013·Therapeutic Delivery·Juan Diego Unciti-BrocetaJose A Garcia-Salcedo
Mar 8, 2014·Pharmaceuticals·Wiebke SihverHans-Jürgen Pietzsch
Apr 3, 2014·Trends in Pharmacological Sciences·Azra Mujić-DelićMartine J Smit
Mar 30, 2013·AJNR. American Journal of Neuroradiology·G SuffrediniL M Levy
Jan 7, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Maria J W D VosjanGuus A M S van Dongen
Sep 10, 2014·Critical Reviews in Oncology/hematology·Roeland LamerisHans J van der Vliet
Jan 20, 2011·Immunological Investigations·Fatemeh RahbarizadehZahra Sharifzadeh
Sep 17, 2010·Expert Review of Molecular Diagnostics·Lieven HuangDirk Saerens
Dec 19, 2014·Expert Opinion on Drug Delivery·Darrell Sleep
Jul 19, 2014·Expert Opinion on Drug Delivery·Matthias D'HuyvetterNick Devoogdt
Oct 1, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Bakheet Elsadek, Felix Kratz
Nov 9, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Isil AltintasRaymond M Schiffelers
Jul 5, 2011·Journal of Proteomics·Robert A HarrisonSimon C Wagstaff
Jul 1, 2010·Drug Discovery Today. Technologies
Jun 9, 2009·Current Opinion in Chemical Biology·Michaela Gebauer, Arne Skerra
Feb 24, 2015·Advanced Drug Delivery Reviews·Jonathan T Sockolosky, Francis C Szoka
Mar 14, 2012·The Journal of Gene Medicine·Thomas WirthSeppo Pasi Antero Ylä-Herttuala
May 23, 2013·Macromolecular Bioscience·Marjoke F DebetsJan C M van Hest
Sep 16, 2011·International Journal of Cancer. Journal International Du Cancer·Hongzheng ZhangDong M Shin
Apr 27, 2011·International Journal of Cancer. Journal International Du Cancer·Rob C RooversPaul M P van Bergen en Henegouwen
Aug 21, 2013·European Journal of Haematology·Tobias Schmidt SlørdahlTorstein Baade Rø
Dec 18, 2009·Journal of Molecular Recognition : JMR·Rebecca L Rich, David G Myszka
Apr 16, 2016·Drug Discovery Today·Sophie SteelandClaude Libert
Mar 10, 2015·International Journal of Biological Macromolecules·S Shirin ShahangianReyhaneh Sariri
Aug 25, 2011·Current Opinion in Biotechnology·Roland E Kontermann
Feb 1, 2015·Molecular Immunology·Christoph SpiessPaul J Carter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Cancer Immunology, Immunotherapy : CII
Rob C RooversPaul M P van Bergen En Henegouwen
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Lea Olive Tchouate GainkamTony Lahoutte
Protein Engineering, Design & Selection : PEDS
Lucy J HoltIan M Tomlinson
International Journal of Cancer. Journal International Du Cancer
Rob C RooversPaul M P van Bergen En Henegouwen
© 2022 Meta ULC. All rights reserved